Journal of Fungi is a premier open-access journal published by MDPI, dedicated to advancing the understanding of fungal biology in its myriad forms. Since its inception in 2015, it has become a vital resource in the fields of ecology, evolution, and plant sciences, attaining notable rankings in Scopus, including Q1 status in Ecology, Evolution, Behavior and Systematics, and Plant Science, with a Q2 ranking in Microbiology (medical). The journal fosters a collaborative platform for researchers, professionals, and students by providing unrestricted access to high-quality, peer-reviewed articles, which encourages the dissemination of innovative findings and methodologies relevant to fungal research. Designed to cater to a global audience, the Journal of Fungi has established its significance in the scientific community, especially from its base in Switzerland, where it continues to contribute to the ongoing discourse in mycology and beyond. With its commitment to open access since its launch and its continuous support for groundbreaking research, the journal plays a crucial role in driving forward the scientific inquiry and ecological awareness in fungal studies.

Fungal Biology, published by Elsevier Science Ltd, is a premier journal dedicated to advancing the field of mycology and its interdisciplinary applications. With an ISSN of 1878-6146 and E-ISSN 1878-6162, this journal serves as a vital platform for researchers and professionals interested in the ecological, evolutionary, and genetic aspects of fungi, as well as their implications in infectious diseases and plant sciences. As of 2023, it proudly holds a Q2 ranking in Ecology, Evolution, Behavior and Systematics and Plant Science, and a Q3 ranking in Genetics and Infectious Diseases, highlighting its significant contribution to these domains. The journal boasts an impressive Scopus rank, including a percentile of 83rd in Ecological studies, ensuring that published research reaches a wide audience and impacts ongoing discourse in the field. With open access options, Fungal Biology encourages the dissemination of high-quality research, aimed to foster collaboration and innovation among scholars and practitioners. With its convergence of knowledge from 2010 to 2024, this journal is instrumental for those advancing the understanding of fungal biology and its myriad applications in environmental and health sciences.

MYCOLOGIA, published by Taylor & Francis Inc, is a prestigious journal that has been at the forefront of fungal research since its inception, with converging years of publication from 1945 to 2024. This interdisciplinary journal, identified by ISSN 0027-5514 and E-ISSN 1557-2536, stands out in various scientific categories, achieving Q1 rankings in Ecology, Evolution, Behavior and Systematics, as well as Plant Science, alongside strong performances in Cell Biology and Molecular Biology categories. With an impact factor that reflects its significance in the field, MYCOLOGIA appeals to a diverse audience, including researchers, professionals, and students dedicated to advancing the understanding of fungal biology and its ecological implications. Notably, while it does not currently operate under an Open Access model, the journal remains a vital resource for those pursuing groundbreaking discoveries in mycology and related disciplines.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

Journal of Pediatric Infection is a vital academic resource dedicated to the ever-evolving field of infectious diseases in pediatric populations. Published by AVES YAYINCILIK in Turkey, this journal features a rigorous peer-review process and has established itself as a platform for innovative research from around the globe. Although currently categorized in the Q4 quartile for both Infectious Diseases and Pediatrics, Perinatology and Child Health, the journal's potential for growth is substantial, attracting contributions that aim to shed light on the complexities of infectious diseases affecting children. With a converged publication history from 2009 to 2024, the journal emphasizes the importance of advancing knowledge in pediatric health through systematic reviews, original research, and case studies. Its open access policy encourages unrestricted sharing of vital research findings, making it an essential read for researchers, clinicians, and students dedicated to improving pediatric healthcare outcomes.

Medical Mycology Journal is a leading publication in the field of medical mycology, dedicated to advancing the understanding and treatment of fungal infections. Published by the Japanese Society of Medical Mycology, this journal serves as an essential resource for researchers, clinicians, and students alike. With an ISSN of 2185-6486 and an E-ISSN of 2186-165X, it aims to provide high-quality peer-reviewed articles focusing on clinical and epidemiological studies, diagnosis, and novel therapeutic approaches related to fungal pathogens. Operating under a Q3 ranking in Infectious Diseases and having consistently published significant findings since its establishment in 2011, the journal is pivotal for those working at the intersection of mycology and infectious disease management. Although currently non-open access, the journal's insights are vital for expanding knowledge in this critical area of healthcare, addressing pressing global health challenges linked to fungal infections.

Current Fungal Infection Reports is an essential academic journal dedicated to the rapidly evolving field of mycology, specifically focusing on the diagnosis, treatment, and epidemiology of fungal infections. Published by Springer, this journal aims to provide a comprehensive platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings and insights into the complexities surrounding fungal diseases. With an ISSN of 1936-3761 and an E-ISSN of 1936-377X, the journal is recognized in the Q3 category for Infectious Diseases as of 2023 and holds a Scopus rank of #199 out of 344 in its field, showcasing its growing influence. Although not currently open access, Current Fungal Infection Reports remains an important resource for those wishing to stay updated on key developments and trends within this critical area of global health. Through its commitment to advancing knowledge and fostering academic exchange, the journal plays a crucial role in combating the challenges posed by fungal infections, making it a must-read for anyone involved in infectious disease research and treatment.

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

International Journal of Mycobacteriology is a peer-reviewed, open-access journal published by Wolters Kluwer Medknow Publications that specializes in the field of infectious diseases with a particular emphasis on mycobacterial research. Since its inception in 2012, this journal has emerged as a vital resource for researchers, healthcare professionals, and students aimed at advancing understanding and treatment of mycobacterial infections, including tuberculosis. With the journal being indexed in Scopus and holding a Q3 ranking in both Infectious Diseases and Microbiology (medical) for 2023, it reflects a substantial contribution to scholarly discourse in these domains, despite its current ranking positioning. Authors and readers benefit from the open access model, ensuring widespread dissemination of research findings and fostering collaboration across the global health community. Located in Mumbai, India, the journal continues to thrive with a commitment to quality research and innovation, welcoming contributions that further the exploration of mycobacteriology throughout the converged years from 2012 to 2024.

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.